Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy
Future Oncology, cilt.18, sa.30, ss.3399-3408, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 30
- Basım Tarihi: 2022
- Doi Numarası: 10.2217/fon-2022-0198
- Dergi Adı: Future Oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.3399-3408
- Anahtar Kelimeler: biopsy, breast cancer, chemotherapy, discordance, estrogen receptor, HER2, neoadjuvant therapy, progesterone receptor, receptor, risk factors
- Van Yüzüncü Yıl Üniversitesi Adresli: Hayır
Özet
Objective: The rates of and the factors influencing HER2 discordance in patients receiving neoadjuvant therapy for breast cancer are investigated. Methods: This study retrospectively examines the rates of HER2 and hormone receptor discordance between the biopsy and postoperative resection specimens of 400 female early-stage breast cancer patients. Results: 133 (33.3%) patients had received neoadjuvant therapy. The rate of HER2 discordance between biopsy and resection specimens was 1.7% in the control group and 5.3% in the neoadjuvant therapy group (p = 0.018). The rate of HER2 discordance was higher in younger patients and in patients with T1 tumors in the neoadjuvant therapy group. Conclusion: Neoadjuvant therapy, age <40 years and smaller tumor size were independent risk factors for HER2 discordance.